(lp0
S'Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap ... Yahoo Finance - 22 hours ago Antares stock has been on a steady rise for the past year. The company develops and manufactures pressure-assisted injector devices that allow patients to self-inject prescription drugs.'
p1
aS'ANTARES PHARMA, INC.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 14, 2017 Antares Pharma, Inc.  is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.'
p2
aS'Antares Pharma Posts Narrower Loss In Q4 - Quick Facts Nasdaq - Mar 14, 2017  - Antares Pharma, Inc.  reported a fourth-quarter net loss of $4.5 million compared to a loss of $6.6 million for the same period in 2015.Antares Pharma reports 4Q loss - Yahoo FinanceWhy Analysts put forward these two stocks: Antares Pharma, Inc. (ATRS ... - The USA Commerce'
p3
aS'Antares Pharma: Realistic Expectations Seeking Alpha - Feb 1, 2017 This article represents an extension to an SA article published December 30, titled &quot;Antares Pharma: Drug Delivery to Multiple Fronts of Profitability&quot;.'
p4
aS'Does Zero-Debt Really Make Antares Pharma Inc  A Financially Strong Company? Simply Wall St - Mar 6, 2017 Any company, including Antares Pharma Inc  with no debt in its capital structure, would maximize capital returns by having an optimal capital structure, which includes debt.'
p5
aS'Antares Pharma: Drug Delivery To Multiple Fronts Of Profitability Seeking Alpha - Dec 30, 2016 Over the last several years, investors in Antares Pharma  have experienced multiple disappointments which prompted many shareholders to exit the shares while remaining holders became increasingly impatient, illustrated in the chart below&nbsp;...'
p6
aS'Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program GlobeNewswire  - Sep 22, 2016 EWING, N.J., Sept. 22, 2016  -- Antares Pharma, Inc.  today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3 study of QuickShot Testosterone &nbsp;...'
p7
aS"Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues Seeking Alpha - Aug 28, 2016 Recently, Mylan  has come under a lot of attention for the price of its Epinephrine Auto-Injector EpiPen. EpiPen price raises left many consumers upset and has even attracted attention from presidential candidates.Plastic Cap Is Crux of Mylan Argument Against Teva's EpiPen - BloombergStop blaming Mylan for the skyrocketing prices on EpiPens - The Hill "
p8
aS'Antares Pharma, Inc.  Stock ABR At 1 Stock Observer - 15 hours ago After closing a study on Antares Pharma, Inc. , the advisors released stock target of $2.825. This estimation is product of Zacks survey, which constituted 4 experts.'
p9
aS'Investors Spotlight: UnitedHealth Group Incorporated , Antares Pharma Inc ... TRA - 20 hours ago UnitedHealth Group Incorporated  posted earnings of $2.11/Share in the previous quarter, as compared to earnings of $2.07/share estimated by analysts.'
p10
a.